MapLight Therapeutics (MPLT) EBITDA (2024 - 2026)
MapLight Therapeutics (MPLT) posted EBITDA of -$83.4 million for Q4 2025, down 164.71% sequentially from -$31.5 million in Q3 2025, and down 266.06% YoY from $50.2 million in Q4 2024.
MapLight Therapeutics (MPLT) EBITDA (2024 - 2026) Analysis & Trends
MapLight Therapeutics has reported EBITDA for 2 years, with the latest figure at -$83.4 million in Q4 2025.
- Quarterly EBITDA fell 266.06% year-over-year to -$83.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$158.5 million (changed N/A YoY) and the FY2025 annual result came in at -$169.1 million, down 103.85% from the prior year.
- EBITDA retreated to -$83.4 million in Q4 2025 per MPLT's latest filing, from -$31.5 million in the prior quarter.
- Over five years, EBITDA peaked at -$20.9 million in Q3 2024 and troughed at -$83.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | MapLight Therapeutics | 533.88 Mn | 533.88 Mn | - | -63.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -63.55 Mn |
| Dec 31, 2025 | -83.38 Mn |
| Sep 30, 2025 | -31.50 Mn |
| Dec 31, 2024 | -22.78 Mn |
| Sep 30, 2024 | -20.89 Mn |